Literature DB >> 19292615

Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts.

Cristina Vincent1, David M Findlay, Katie J Welldon, Asiri R Wijenayaka, Timothy S Zheng, David R Haynes, Nicola L Fazzalari, Andreas Evdokiou, Gerald J Atkins.   

Abstract

We have recently shown that TNF-related weak inducer of apoptosis (TWEAK) is a mediator of inflammatory bone remodeling. The aim of this study was to investigate the role of TWEAK in modulating human osteoblast activity, and how TWEAK and TNFalpha might interact in this context. Recombinant TWEAK and TNF were both mitogenic for human primary osteoblasts (NHBC). TWEAK dose- and time-dependently regulated the expression of the osteoblast transcription factors RUNX2 and osterix. TWEAK inhibited in vitro mineralization and downregulated the expression of osteogenesis-associated genes. Significantly, TWEAK and TWEAK/TNF induced the expression of the osteoblast differentiation inhibitor and SOST gene product, sclerostin. Sclerostin induction was mitogen-activated protein kinase (MAPK) dependent. The SOST mRNA levels induced by TWEAK were equivalent to or exceeded those seen in steady-state human bone, and the TWEAK/TNF induction of SOST mRNA was recapitulated in fresh cancellous bone explants. TWEAK-induced sclerostin expression was observed in immature osteoblastic cells, both in cycling (Ki67(+)) primary NHBC and in the cell lines MC3T3-E1 and MG-63, as well as in human osteocyte-like cells and in the osteocyte cell line, MLO-Y4. Treatment of NHBC with recombinant human sclerostin mimicked the effects of TWEAK to suppress RUNX2 and osteocalcin (OCN). TWEAK, TNF, and sclerostin treatment of NHBC similarly altered levels of phosphorylated and total GSK3beta and active and total levels of beta-catenin, implying that the Wnt signaling pathway was affected by all three stimuli. Sclerostin also rapidly activated ERK-1/2 MAPK signaling, indicating the involvement of additional signaling pathways. Together, our findings suggest that TWEAK, alone and with TNF, can regulate osteoblast function, at least in part by inducing sclerostin expression. Our results also suggest new roles and modes of action for sclerostin.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19292615     DOI: 10.1359/jbmr.090305

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  52 in total

Review 1.  Osteocyte regulation of bone mineral: a little give and take.

Authors:  G J Atkins; D M Findlay
Journal:  Osteoporos Int       Date:  2012-08       Impact factor: 4.507

Review 2.  Inflammatory bone loss: pathogenesis and therapeutic intervention.

Authors:  Kurt Redlich; Josef S Smolen
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

3.  Dose-specific effects of tumor necrosis factor alpha on osteogenic differentiation of mesenchymal stem cells.

Authors:  H Huang; N Zhao; X Xu; Y Xu; S Li; J Zhang; P Yang
Journal:  Cell Prolif       Date:  2011-10       Impact factor: 6.831

Review 4.  Role of TWEAK in lupus nephritis: a bench-to-bedside review.

Authors:  Jennifer S Michaelson; Nicolas Wisniacki; Linda C Burkly; Chaim Putterman
Journal:  J Autoimmun       Date:  2012-06-22       Impact factor: 7.094

Review 5.  Periprosthetic osteolysis after total hip replacement: molecular pathology and clinical management.

Authors:  Donald W Howie; Susan D Neale; David R Haynes; Oksana T Holubowycz; Margaret A McGee; Lucian B Solomon; Stuart A Callary; Gerald J Atkins; David M Findlay
Journal:  Inflammopharmacology       Date:  2013-10-15       Impact factor: 4.473

6.  Cadmium exposure activates the ERK signaling pathway leading to altered osteoblast gene expression and apoptotic death in Saos-2 cells.

Authors:  Kate S Arbon; Cody M Christensen; Wendy A Harvey; Sara J Heggland
Journal:  Food Chem Toxicol       Date:  2011-10-13       Impact factor: 6.023

7.  Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism.

Authors:  Gerald J Atkins; Peter S Rowe; Hui P Lim; Katie J Welldon; Renee Ormsby; Asiri R Wijenayaka; Lesya Zelenchuk; Andreas Evdokiou; David M Findlay
Journal:  J Bone Miner Res       Date:  2011-07       Impact factor: 6.741

Review 8.  Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease.

Authors:  Michelle M McDonald; Jesus Delgado-Calle
Journal:  Curr Osteoporos Rep       Date:  2017-12       Impact factor: 5.096

9.  Bone Mineral Density, Bone Turnover, and Systemic Inflammation in Non-cirrhotics with Chronic Hepatitis C.

Authors:  Jennifer C Lai; Dolores M Shoback; Jacob Zipperstein; Blanca Lizaola; Samuel Tseng; Norah A Terrault
Journal:  Dig Dis Sci       Date:  2015-01-07       Impact factor: 3.199

10.  Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment.

Authors:  A H van Lierop; A W van der Eerden; N A T Hamdy; A R Hermus; M den Heijer; S E Papapoulos
Journal:  J Clin Endocrinol Metab       Date:  2012-07-27       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.